Objective: The paper proposes recommendations for continuously promoting the work of the National Medical Insurance Price Negotiation (NMIPN) and further harnessing the value and strategic purchasing strengths of medical insurance funds. Methods: Descriptive statistical method was applied to comprehensively review NMIPN drugs and their supply enterprises from 2016 to 2024. Additionally, the synergistic effects of NMIPN and National Volume-Based Procurement (NVBP) policies were analyzed. Results: Since 2019, the annual number, success rate and average price reductions remained at over 85, 58% and 55%, respectively. Drug categories expanded from 2 to 21, and the formulation increased from 1 to 23. 34 NMIPN drugs transferred to NVBP, experiencing a secondary price reduction ranging from 58.06% to 98.86%. 235 pharmaceutical companies participated in NMIPN, with an increasing trend. The percentage of Chinese companies has increased since 2019, and the proportion of new enterprises has slightly decreased. Conclusions: While expanding the scope of NMIPN, continuous optimization of drug selection and monitoring mechanism remains imperative, and substantial support for "true innovation" in NMIPN drugs is necessary. Under the functional positioning of "basic security", the NMIPN and NVBP policies operated synergistically to achieve the expansion of the list of medical insurance drugs and multiple significant price reductions and promote the market expansion and innovative transformation of pharmaceutical companies and high-quality development of the pharmaceutical industry, following the adjustment strategy of "making up for shortcomings" and the implementation principle of "meeting the clinical needs". It is suggested that a certain buffer period should be considered in the process of normalizing NMIPN and NVBP policies, to alleviate the impact of consecutive price reductions on the sustainable development capability and innovation drive of pharmaceutical enterprises. Meanwhile, efforts should be made to explore diverse value realization paths of innovative drugs.
Key words
medical insurance price negotiation /
volume-based procurement /
category evolution /
drug price formation /
policy synergy
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 国务院办公厅.关于完善公立医院药品集中采购工作的指导意见[EB/OL].(2015-02-28)[2025-04-21].https://www.gov.cn/zhengce/content/2015-02/28/content_9502.htm.
[2] 王宁锋,李雪竹,张慧.国谈药单行支付政策研究[J].卫生经济研究,2024,41(06):16-18.
[3] 胡善联. 中国医保药品价格谈判回顾和展望[J].卫生经济研究,2024,41(01):9-13.
[4] 彭博,姜骁桐,张小娟,等.国家医保谈判药品“双通道”管理实施现状与政策分析[J].中国卫生政策研究,2024,17(05):9-16.
[5] 晏紫乐,雷清强,胡敏.国家医保谈判药品可及性的研究进展[J].世界临床药物,2025,46(01):87-94.
[6] 李伟,陈红斗,陆伟,等.2016—2021年国家医保谈判药品可及性研究——基于全国大数据的实证分析[J].中国现代应用药学,2023,40(10):1405-1410.
[7] 彭瑾,蒋俊男,邱增辉,等.国家医保谈判药品在浙江省三级医疗机构的落地实践[J].中国药房,2023,34(10):1159-1164.
[8] 李凯悦,刘辉,蒋倩.历年国家医保谈判药品概况与分析——抗肿瘤药品专题[J].肿瘤药学,2021,11(02):229-235.
[9] 刘丹,刘吉芳,龙葵英,等.国家组织药品集中采购和医保谈判政策对公立医疗机构与社会药房的影响[J].中国药业,2024,33(20):12-15.
[10] 易洪彬,石丰豪,蒯丽萍,等.集中带量采购和医保谈判政策对表皮生长因子受体酪氨酸激酶抑制剂药品采购的影响——以吉非替尼和奥希替尼为例[J].中国药物经济学,2024,19(03):25-30.
[11] 陈彤丹,高奇隆,罗丹,等.医保制度改革对医院慢性病药物可及性影响的探索性研究——基于一线临床与药学工作实践[J].中国现代应用药学,2022,39(24):3300-3305.
[12] 冯雨莉,汤少梁.国家医保谈判和药品集中带量采购对制药企业的财务绩效、研发投入强度与销售费用率的影响[J].医学与社会,2024,37(08):136-144.
[13] 谭清立,郭润镒,孙慧琳,等.药品集中带量采购与医保谈判政策的协同作用[J].中国药房,2021,32(15):1793-1799.
[14] 国务院办公厅.国家药品价格谈判取得重要进展和成果[EB/OL].(2016-05-20)[2025-04-26].https://www.gov.cn/xinwen/2016-05/20/content_5075021.htm.
[15] 国务院办公厅.国家药品价格谈判有关情况说明[EB/OL].(2016-05-20)[2025-04-21].https://www.gov.cn/xinwen/2016-05/20/content_5075025.htm.
[16] 人力资源和社会保障部.人社部发布医保药品目录准入谈判结果[EB/OL].(2017-07-19)[2025-04-21].https://www.gov.cn/xinwen/2017-07/19/content_5211741.htm#1.
[17] 国家医疗保障局.关于发布2018年抗癌药医保准入专项谈判药品范围的通告[EB/OL].(2018-08-17)[2025-04-21].https://www.gov.cn/xinwen/2018-08/17/content_5314405.htm.
[18] 中国医疗保险.医保谈判:寻求价格与创新之间的“最大公约数”[EB/OL].(2024-12-11)[2025-05-06].https://mp.weixin.qq.com/s/6Y55Q364s1ozsJgXtfyt0g.
[19] 新闻坊.国家医保局:不会再和辉瑞单独谈判！为何谈判失败?细节披露→[EB/OL].(2023-01-19)[2025-05-06].https://mp.weixin.qq.com/s/wjuljl6uuLPg2TDA7t8vOQ.
[20] 中国医疗保险.为何28种药物医保谈判失败?国家医保局解读[EB/OL].(2024-12-11)[2025-05-06].https://mp.weixin.qq.com/s/ki561TuyXTgHliJhLxBfMA.
[21] 国家医疗保障局.国家医疗保障局关于公布《2022年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案》及相关文件的公告[EB/OL].(2022-06-29)[2025-05-08].https://www.nhsa.gov.cn/art/2022/6/29/art_109_8342.html.
[22] 中国医疗保险.待到山花烂漫时——2021年国家医保目录调整展望[EB/OL].(2021-06-29)[2025-05-08].https://mp.weixin.qq.com/s/AgmyCXugGF4ITI1V_nUy7A.
[23] 牛奔,李平平,柴语鹃.集中带量采购中选药品价格差异变化及地区分布演变研究[J].中国卫生事业管理,2025,42(05):538-545.
[24] 毛凯峰,虞杰,王琳宁,等.医保视角下新药创新性认定与价格管理政策的国际对比分析[J].中国药房,2024,35(15):1801-1806.
[25] 新华社.哪些药品有望进医保?谈判药品如何续约?——2022年国家医保目录调整“划重点”[EB/OL].(2022-06-16)[2025-05-06].https://www.gov.cn/zhengce/2022-06/16/content_5696063.htm.
[26] 王奇巍,叶亚婧,郭文.中国创新药鼓励政策改革进展与成果[J].中国新药杂志, 2024,33(13):1297-1302.
[27] 国家医疗保障局.国家医保局2023年国家基本医疗保险、工伤保险和生育保险药品目录调整新闻发布会实录[EB/OL].(2023-12-13)[2025-05-30].https://www.nhsa.gov.cn/art/2023/12/13/art_14_11684.html.
[28] 21经济网.集采推动医保“腾笼换鸟”,创新药“跑步前进”惠及更多国人[EB/OL].(2024-03-01)[2025-05-30].https://www.21jingji.com/article/20240301/herald/b7500e049d20fd908d596fc564bc7fae.html.
[29] 国家医疗保障局.《2022年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案》及相关文件的解读[EB/OL].(2022-06-29)[2025-05-17].https://www.nhsa.gov.cn/art/2022/6/29/art_38_8338.html.
[30] 陶立波,王芳旭.医保药品准入谈判的“量价互换”机制探讨[J].中国医疗保险,2024(05):5-9.
